CLEVELAND, Ohio (May 13, 2026)—Osteoporosis, which is highly prevalent in postmenopausal women, has long been associated with an increased risk of fractures. A new study suggests it may also increase a woman’s overall risk of death—by as much as 47%—especially within specific ranges of bone mineral density (0.46-0.71 g/cm² for total femur bone mineral density). Results of the study are published online today in Menopause, the journal of The Menopause Society.

Duke-NUS Medical School has broadened access to medicine for students across various academic backgrounds, including Chinese medicine and honours college programmes.The move reinforces Duke-NUS’ commitment to developing clinicians equipped to shape the evolving healthcare landscape.

Onerous caring responsibilities reduce brain function for people aged 50 and over, whereas light caring duties can actually be beneficial to middle-aged and older people’s mental abilities, a new UCL study finds.

Aerobic and resistance training combined, and high intensity interval training (HIIT), are associated with significant reductions in blood pressure over 24 hours, finds a pooled data analysis of the available evidence for several different types of structured exercise, and published online in the British Journal of Sports Medicine.

Mothers who work in jobs where they are frequently exposed to toxic chemicals or experience high stress have higher odds of having a child with autism spectrum disorder (ASD), suggest the findings of original research published online in the journal Occupational & Environmental Medicine.

The first update to guidance on pharmacological management of obesity and its complications, issued by the European Association for the Study of Obesity (EASO) and published in Nature Medicine, adds new evidence from multiple randomised clinical trials. The updated ‘algorithm’ is presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May).

New research presented at this year’s European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times more likely to maintain that weight loss by continuing on MTD than those who stop treatment, while those who switch to a lower dose of 5 mg are four times more likely to maintain weight loss than those who stop. The study is by Dr Deborah Horn, Director of the Center for Obesity Medicine and Metabolic Performance at McGovern Medical School at UTHealth Houston, Houston, Texas, USA, and colleagues. The study was funded by Eli Lilly and Company, the manufacturer of tirzepatide.